- Market Radar
- /
- MYNZ
Sagehood
Financial Analyst
PREMIUM
Technical Trader
PREMIUM
Valuation Projection
PREMIUM
Social Media Buzz
PREMIUM
News Agent
PREMIUM
Macro Economist
PREMIUM
About MYNZ
7/28/2025
Comprehensive Analysis
Financial Health
- Balance Sheet & Liquidity: Mainz Biomed (MYNZ) improved equity from -€4.14B in mid-2024 to +€6.05B by year-end, driven by capital raises. However, the current ratio (1.32) and quick ratio (1.11) remain fragile, with €6.24B cash reserves offset by negative operating cash flow (-€17.09B TTM). The debt-to-equity ratio (0.37) is moderate, but the company’s reliance on financing (€4M follow-on in July 2025) highlights liquidity risks.
Free Insights for Smarter Investing
Get 5 daily AI-powered insights on your favorite stocks-absolutely free.
Free Account
- View 5 tickers daily
- Create and manage Watchlists
- Import portfolios (no personalized insights)
- Chat with the general Sagehood AI Agent
- Market Radar: Preview access only
Premium Membership
- Unlimited AI-generated insights across all sections
- Market Overview
- Market Radar (AI-driven investment opportunities)
- Access to all Sagehood AI agents, including domain-specific experts
- Personalized insights and actionable recommendations for smarter investing